CMS Grants NTAP Status to YARTEMLEA, Boosting Hospital Reimbursement for Omeros' TA-TMA Drug
OMER has more than doubled off its 52-week low of $3.435.
Summary
CMS granted New Technology Add-On Payment (NTAP) status to YARTEMLEA, Omeros' only FDA-approved treatment for TA-TMA. Starting October 1, 2026, hospitals treating Medicare patients with YARTEMLEA can receive up to $287,079 in additional reimbursement per case. This directly addresses a key adoption barrier — hospital budget constraints — and should accelerate uptake among the ~30% of allogeneic transplant patients covered by Medicare. The decision follows the drug's strong Q1 commercial launch and recent EMA setback, reinforcing the U.S. revenue trajectory. With no prior NTAP news in the timeline, this is a fresh, material positive for the commercial story.
At the time of this announcement, OMER was trading at $12.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $856.9M. The 52-week trading range was $3.44 to $17.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.